A promoter polymorphism in cholesterol 7α-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin

Atherosclerosis

Volumn 180, Issue 2, 2005, Pages 407-415

  Kajinami, Kouji ^a,b,c   Brousseau, Margaret E ^a,b   Ordovas, Jose M ^a,b   Schaefer, Ernst J ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY   (United States)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Apolipoprotein E; Cholesterol 7 hydroxylase; Low density lipoprotein cholesterol; Pharmacogenetics; Statin

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; ATORVASTATIN; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYTOCHROME P450 ISOENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; WILD TYPE;

AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS E; BILE ACIDS AND SALTS; CHOLESTEROL 7-ALPHA-HYDROXYLASE; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LOVASTATIN; MALE; MIDDLE AGED; PLACEBOS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PYRROLES; SEX FACTORS; TREATMENT OUTCOME;

EID: 22744439625     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.12.019     Document Type: Article

References (17)

1. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. US Department of Health and Human Services; Public Health Service; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 02-5215, September 2002.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
3. J. Shepherd, G.J. Blauw, M.B. Murphy on behalf of the PROSPER study group Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
4. R. Weinshilboum Inheritance and drug response N Eng J Med 348 2003 529 537
5. W.E. Evans, and H. McLeod Pharmacogenomics. Drug disposition, drug targets, and side effects N Engl J Med 348 2003 538 549
6. J. Pedro-Botet, E.J. Schaefer, and R.G. Bakker-Arkema Apolipoprotein E genotype affects plasma lipid response to atrovastatin in a gender specific manner Atherosclerosis 158 2001 183 193
7. D.I. Chasman, D. Posada, and L. Subrahmanyan Pharmacogenetic study of statin therapy and cholesterol reduction JAMA 291 2004 2821 2827
8. J.H. Moore, and S.M. Williams New strategies for identifying gene-gene interactions in hypertension Ann Med 34 2002 88 95
9. J. Wang, D.J. Freeman, and S.M. Grundy Linkage between cholesterol 7a-hydroxylase and high plasma low-density lipoprotein cholesterol concentrations J Clin Invest 101 1998 1283 1291
10. P. Couture, J.D. Otvos, and L.A. Cupples Association of the A-204C polymorphism in the cholesterol 7α-hydroxylase gene with variations in plasma low density lipoprotein cholesterol levels in the Framingham Offspring Study J Lipid Res 40 1999 1883 1889
11. R.A. Hegele, J. Wang, and S.B. Harris Variable association between genetic variation in the CYP7 gene promoter and plasma lipoproteins in three Canadian populations Atherosclerosis 154 2001 579 587
12. Z. Han, S.C. Heath, and D. Shmulewitz Candidate genes involoved in cardiovascular risk factors by a family-based association study on the Island of Kosrae, Federated States of Micronesia Am J Med Genet 110 2002 234 242
13. C.R. Pullinger, C. Eng, and G. Salen Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype J Clin Invest 110 2002 109 117
14. M. Davidson, J. McKenney, and E. Stein Comparison of 1 year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia Am J Cardiol 79 1997 1475 1481
15. S.K. Cheema, D. Cikaluk, and L.B. Agellon Dietary fats modulate the regulatory potential of dietary cholesterol on cholesterol 7α-hydroxylase gene expression J Lipid Res 38 1997 315 323
16. D. Wang, D. Stroup, and M. Marrapodi Transcriptional regulation of the human cholesterol 7α-hydroxylase gene (CYP7A) in HepG2 cells J Lipid Res 37 1996 1831 1841
17. A.D. Cooper, J. Chen, and M.J. Botelho-Yetkinler Characterization of hepatic-specific regulatory elements in the promoter region of the human cholesterol 7α-hydroxylase gene J Biol Chem 272 1997 3444 3452